Rani Therapeutics Holdings (RANI) Net Cash Flow (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Net Cash Flow of -$9.0 million for Q1 2026, down 241.35% year-over-year from $6.3 million in Q1 2025, and down 163.35% quarter-over-quarter from $14.2 million in Q4 2025.
Rani Therapeutics Holdings (RANI) Net Cash Flow (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$9.0 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 241.35% year-over-year to -$9.0 million; the TTM figure through Mar 2026 stood at -$767000.0 (down 123.72% YoY), while the FY2025 annual figure was $14.6 million, up 792.48% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$9.0 million, down from $14.2 million in the prior quarter.
- The five-year high for Net Cash Flow was $14.2 million in Q4 2025, with the low at -$69.5 million in Q3 2022.
- The 5-year median for Net Cash Flow is -$2.4 million (2024), against an average of -$6.3 million.
- Peak annual rise in Net Cash Flow reached 2850.68% in 2025, while the deepest fall reached 2477.64% in 2025.
- Rani Therapeutics Holdings' Net Cash Flow stood at -$212000.0 in 2022, then surged by 520.75% to $892000.0 in 2023, then plunged by 157.74% to -$515000.0 in 2024, then soared by 2850.68% to $14.2 million in 2025, then plunged by 163.35% to -$9.0 million in 2026.
- Business Quant data shows RANI's Net Cash Flow at -$9.0 million in Q1 2026, $14.2 million in Q4 2025, and -$6.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.20 Bn | 131.35 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.09 Bn | 78.10 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.04 Bn | 9.65 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.50 Bn | - | 225.59 Mn |
| 10 | Rani Therapeutics Holdings | 166.99 Mn | 166.99 Mn | - | -4.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.77 Mn |
| Jun 30, 2026 | -4.77 Mn |
| Mar 31, 2026 | -8.97 Mn |
| Mar 31, 2026 | -8.97 Mn |
| Dec 31, 2025 | 14.17 Mn |
| Dec 31, 2025 | 14.17 Mn |
| Sep 30, 2025 | -6.11 Mn |
| Sep 30, 2025 | -6.11 Mn |
| Jun 30, 2025 | 150,000.00 |
| Jun 30, 2025 | 150,000.00 |
| Mar 31, 2025 | 6.35 Mn |
| Mar 31, 2025 | 6.35 Mn |
| Dec 31, 2024 | -515,000.00 |
| Dec 31, 2024 | -515,000.00 |
| Sep 30, 2024 | -237,000.00 |
| Sep 30, 2024 | -237,000.00 |
| Jun 30, 2024 | -2.36 Mn |
| Jun 30, 2024 | -2.36 Mn |
| Mar 31, 2024 | 1.01 Mn |
| Mar 31, 2024 | 1.01 Mn |